Shared Decision Making in Graves Disease - Graves Disease (GD) Choice

计划入组 93 人 · 首次发布于 2014 年 4 月 8 日

Radioactive Iodide Therapy for Pediatric Graves' Disease

计划入组 19 人 · 首次发布于 2011 年 1 月 4 日

Observation in the Treatment of Graves' Disease

计划入组 1,000 人 · 首次发布于 2021 年 9 月 14 日

thyroid-stimulating hormone receptor antagonist (graves disease/thyroid eye disease)

liver disease program

siRNA therapeutics for ocular disease/dermatological disease (Phio Pharmaceuticals)

Rare Disease Research, LLC

CASTLEMAN DISEASE COLLABORATIVE NETWORK

United States

CURE RARE DISEASE, INC.

United States

Immunovant's Batoclimab Shows Promise in Graves' Disease Phase II Trial; IMVT-1402 Pivotal Trial Planned

Immunovant's IMVT-1402 Shows Promise in Graves' Disease Treatment

Immunovant's Batoclimab Shows Sustained Remission in Graves' Disease Patients Six Months After Treatment